MARVAL SOFTWARE LIMITED
Company number 02425318 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: MARVAL SOFTWARE LIMITED (Company No. 02425318)
1. Financial Health Score: C — Guarded / Fair
Grade explanation:
The company is active, solvent on paper, and up to date with its filings—equivalent to a patient who is conscious and stable. However, its equity base has shrunk sharply in one year, cash reserves are thin relative to obligations, and the directors’ own statements in the filed accounts acknowledge a material uncertainty over the company’s ability to continue as a going concern. This is not a critical condition, but it is a serious warning sign that requires treatment and close monitoring. Without improvement, the grade could deteriorate; with disciplined action, it could recover to a B.
2. Key Vital Signs
| Vital Sign | Latest Figure (2024) | Prior Year (2023) | Interpretation |
|---|---|---|---|
| Net Assets (solvency) | £2,234,393 | £3,449,805 | Positive, but down roughly 35% in one year. The company’s “body mass” (equity) is falling. |
| Cash at Bank | £240,110 | £259,457 | Low. Covers only about 12% of current liabilities—like low blood pressure. |
| Current Assets | £3,201,644 | £4,414,410 | Falling, largely because debtors have dropped. |
| Current Liabilities | £1,958,887 | £2,167,184 | Moderate and slightly lower, but still nearly eight times the cash balance. |
| Current Ratio | 1.63 | 2.04 | Above 1.0, so short-term obligations can theoretically be met, but the ratio is weakening. |
| Debtor Reliance | £2,961,534 (~92% of current assets) | £4,154,953 | Very high concentration in receivables. If customers pay slowly, cash flow could seize up. |
| Shareholders’ Funds | £2,234,393 | £3,449,805 | Reserves fell by about £1.22m, implying a substantial loss for 2024 (no profit and loss account is filed). |
| Long-Term Borrowings | £41,194 | £88,339 | Very low gearing—little long-term debt, which is a positive structural sign. |
| Filing Compliance | Up to date | Up to date | Accounts and confirmation statement are current. Good regulatory “vital sign.” |
Medical analogy: The company has a pulse and is not in collapse, but it is showing signs of financial anaemia (falling reserves), dehydration (low cash), and partially blocked arteries (a large debtor book that must be converted into cash).
3. Diagnosis
Overall condition: Guarded. The company is not insolvent, but its financial health has weakened materially.
What the data reveals:
- Equity erosion: Net assets fell from £3.45m to £2.23m between 2023 and 2024. Because no profit and loss account is included in the public filing (the company used the small-company exemption), the exact trading result cannot be verified from the accounts, but the movement in reserves implies a significant operating loss in 2024.
- Going concern uncertainty: The accounts state that the directors acknowledge a material uncertainty over the company’s ability to continue as a going concern. They attribute the position to a deliberate period of repositioning and reinvestment during 2024 and 2025, expecting benefits from 2026 onwards. Until that strategy bears fruit, the company remains vulnerable.
- Liquidity concentration: Cash is low, and current assets are dominated by debtors (£2.96m). This means the company’s short-term survival depends heavily on customers paying invoices promptly.
- Asset base contraction: Total assets fell from £5.71m to £4.24m, driven by lower debtors and amortisation of intangible assets.
- Low debt burden: There is little long-term debt, which reduces the risk of forced insolvency from loan covenants, but also means the company has limited external financing cushion beyond its own reserves.
Bottom line: The company is in a “treatment phase.” It is stable enough to continue trading today, but the combination of shrinking reserves, thin cash, and a stated going-concern uncertainty means it is not yet out of the woods.
4. Recommendations
-
Introduce a 13-week rolling cash-flow forecast
Monitor liquidity weekly, like checking a patient’s pulse. Given the low cash balance and heavy reliance on debtors, early warning of a cash shortfall is essential. -
Strengthen credit control on the £2.96m debtor book
Tighten payment terms, chase overdue invoices aggressively, and consider invoice discounting or factoring to convert receivables into cash faster. -
Review the cost base during the repositioning period
The directors describe 2024–2025 as a period of reinvestment. Ensure that spending is tightly aligned with expected revenue so that reserves do not continue to erode faster than the strategy can generate returns. -
Build a minimum cash buffer
Aim to hold cash equivalent to at least several months of operating costs to reduce vulnerability to delayed customer payments. -
Prepare monthly management accounts, including a profit and loss account
Since the statutory filing omits the profit and loss account, internal monthly reporting will help the board spot profitability problems before they show up in year-end reserves. -
Reassess the going-concern position at every reporting date
The board should formally revisit the going-concern assumption regularly and keep shareholders and the parent entity informed if uncertainty persists or deepens. -
Maintain strict filing discipline
Continue submitting accounts and confirmation statements on time to avoid penalties and preserve regulatory good standing.